ArticleHeliyon2024
Bioinformatics
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Crosstalk between alternative splicing and non-coding RNAs in hepatocellular carcinoma: from regulatory mechanism to therapeutic implications.Non-coding RNA research · 2026Review
- Specific muscle targeted delivery of miR-130a loaded lipid nanoparticles: a novel approach to inhibit lipid accumulation in skeletal muscle and obesity.Journal of nanobiotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to explore key microRNAs (miRNAs) and their effects on hepatocellular carcinoma (HCC) progression. Methods: Key deregulated miRNAs in HCC were screened from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The anti-cancer effects of miR-486-5p were validated using a cell counting kit-8 assay, flow cytometry, scratch assay, transwell assay, and an orthotopic transplantation tumor model. Furthermore, the expression, clinical significance, and function of miR-486-5p and its targets were predicted using bioinformatics. Additionally, a luciferase reporter assay was performed to validate the miR-486-5p target. Results: By integrating multiple datasets from TCGA and GEO databases, we identified miR-486-5p as the only lowly expressed miRNA in HCC, whose expression was also associated with clinical features. Additionally, miR-486-5p exhibited anti-cancer properties both Conclusion: miR-486-5p suppresses cancer progression in HCC by interacting with SRSF3. Therefore, miR-486-5p and SRSF3 may serve as promising therapeutic targets for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.